Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy. by Katsumoto, Y. et al.
British Journal of Cancer(1996) 73, 110-116
O" © 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by
local immunotherapy
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Summary We previously reported that the anti-tumour effect of OK-432 is considerably enhanced by its
intratumoral injection together with fibrinogen. In the present study, we generated killer T cells by culturing
tumour-infiltrating lymphocytes from thyroid cancer patients who had received this local immunotherapy.
Phenotypic analysis revealed that the T cells were positive for CD3+, CD4+, Leu8-, CD45RO+ and T-cell
receptor (TCR)aop, as well as showing strong surface expression of HLA-DR, CD25, LFA-1 and ICAM-1.
The generated CD4+ T cells secreted interferon (IFN)-y, tumour necrosis factor (TNF)-a, TNF-P, and
interleukin (IL)-6 (but not IL-4), and exhibited a high level of cytolytic activity against several tumour cell
lines. The cytolytic activity of these T cells for Daudi cells was inhibited by preincubation with an anti-
intercellular adhesion molecule (ICAM)-l antibody, but not by preincubation with anti-TCRap. anti-CD2, or
anti-LFA-l antibodies. Pretreatment with anti-ICAM-l antibody inhibited T-cell cytolytic activity, but not
conjugation with target cells. In addition, incubation with immobilised anti-ICAM-1 enhanced the secretion of
IFN-y by T cells. We conclude that ICAM-1 expressed on the effector cytotoxic CD4+ T lymphocytes delivers
regulatory signals that enhance IFN-y secretion.
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The streptococcal preparation OK-432 is an immunos-
timulator produced by treating the Su strain of Streptococcus
pyogenes with heat and penicillin, and it has been recognised
as one of the most effective biological response modifiers
(BRMs) for augmenting host immunity (Katano and Torisu,
1983; Torisu et al., 1983; Uchida et al., 1984; Watanabe &
Iwa, 1987; Haruna et al., 1990). We have previously shown
that the anti-tumour activity of OK-432 is considerably
enhanced by intratumoral injection together with fibrinogen
(Monden et al., 1992). This local immunotherapy effectively
induces the marked infiltration of inflammatory cells into the
tumour stroma on the day after injection and can contribute
to tumour regression. We have also demonstrated that the
regional lymph nodes of cancer patients receiving this local
immunotherapy were a useful source of competent B lym-
phocytes for the establishment of human-human hybridomas
(Baba et al., 1992; Yagyu et al., 1993), and we have estab-
lished cytotoxic CD4+ T-cell clones from such lymph nodes
(Nagaoka et al., 1992). In the present study, we generated
cytotoxic CD4+ T cells from the tumour-infiltrating lym-
phocytes (TILs) of thyroid cancer patients who had received
the intratumoral injection of OK-432 with fibrinogen.
CD4 and CD8 are cell-surface molecules that are expressed
on mutually exclusive subsets of T lymphocytes. CD8+ T
lymphocytes mediate cytotoxic activity against target cells
that are recognised in an MHC class I-restricted fashion.
In contrast, the major function of CD4+ T cells, which
recognise antigens that bind to MHC class II molecules, is to
promote antibody production by B cells and the secretion of
a number of biologically important cytokines. Several reports
have documented that both CD4+ and CD8+ cells show
cytolytic activity when activated by target cells bearing the
appropriate antigen or by non-specific stimulants (Fleischer,
1984; Tite et al., 1985; Noguchi et al., 1989; Erb et al., 1990;
Ju et al., 1990). Cytolysis mediated by CD8+ T lymphocytes
is now well documented, but as is the case for CD4+ cells,
the mechanisms involved are still controversial (Nagaoka et
al., 1992; Nishimura et al., 1992; Ozdemirli et al., 1992;
Apasov et al., 1993).
The adhesion molecules expressed on T lymphocytes are
crucial for stabilising cell-cell interactions. They were first
thought to be accessory molecules that simply joined one cell
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to another. Recently, it has been realised that these molecules
also transmit signals from outside the cell to the inside
(Wachlotz et al., 1989; van Seventer et al., 1991; Galandrini
et al., 1992). Intercellular adhesion molecule-I (ICAM-1) is a
major ligand for LFA-1 (CDlla/CD18), Mac-l (CDllb/
CD18), and the major group of rhinoviruses. It is expressed
on a variety of cells in inflammatory lesions and is induced in
vivo and in vitro by cytokines such as interleukin(IL)-1,
tumour necrosis factor (TNF)-a, or interferon (IFN)-y (Spr-
inger, 1990; Rothlein et al., 1986; Rothlein and Wegner,
1992).
In this study, we analysed the characteristics and the kill-
ing mechanisms of cytotoxic CD4+ T lymphocytes generated
by local immunotherapy, as well as the role of ICAM-1
expression of these T cells in the cytotoxic activity of these
cells.
Materials and methods
Local immunotherapy
A solution for immumotherapy was prepared by dissolving 5
Klinische Einheit (KE; 1 KE corresponds to 0.1 mg of
lyophilised Streptococcus pyogenes) of OK-432 (Chugai Phar-
maceutical, Tokyo, Japan),ain 1 ml of aprotinin (1000 Kal-
likrein Inhibitor Einheit; KIE), and adding 80 mg of human
heat-inactivated fibrinogen (Beriplast P; Behring-Werke,
Marburg, Germany) containing blood coagulation factor
XIII to produce OK-432/fibrinogen solution (OK-432/fbg).
At 4-7 days before surgery, seven patients with thyroid
cancer received the intratumoral injection of this solution.
Preparation of TILsfrom surgical specimens
Under sterile condition, surgically resected tumour specimens
were immediately minced with scissors and incubated for 2 h
at 37°C in AIM-V medium (Gibco, NY, USA) containing
type IV collagenase (200 U ml-', Sigma, MO, USA),
hyaluronidase (30 U ml-', Sigma), and deoxyribonuclease
(100 Lg ml-1, Sigma). After passage through a nylon mesh to
remove undigested tissue fragments, the cells were cent-
rifuged on lymphocyte separation medium (LSM; Organon
Tecknica, NC, USA). Then the TILs at the interface were
collected, washed and resuspended in the same medium.Generation ofcytotoxic T lymphocytes
TILs from patients pretreated with OK-432/fbg were cultured
in AIM-V medium containing 1000 U ml-' of recombinant
IL-2 (Shionogi Pharmaceutical, Osaka, Japan). Cells adhe-
rent to the plastic plate were removed and non-adherent cells
were stimulated biweekly with 0.05 KE ml-' of OK-432. This
resulted in the selective growth of CD4+ T lymphocytes after
4 weeks of incubation. As a control, TILs were harvested
from patients without local immunotherapy and cultured
under the same conditions.
Flow cytometric analysis
Flow cytometric analysis of lymphocyte surface phenotypes
was carried out by direct immunofluorescence using a FACS-
can (Becton Dickinson, Mountain View, CA, USA). Lym-
phocytes were incubated for 30 min at 4°C with 20tlI of the
appropriate dilution of the following fluorescein
isothiocyanate (FITC)-conjugated or phycoerythrin (PE)-
conjugated monoclonal antibodies: anti-Leu 4 (CD3), anti-
Leu 2a (CD8), anti-Leu 3a (CD4), anti-Leu 8, anti-CD2
(LFA-2), anti-HLA-DR for HLA Class II, anti-CD25 for
p55-IL-2 receptor, anti-TCR-1 (TCRap), anti-Leu45RO
(CD45RO), anti-Leu 18 (CD45RA) (Becton Dickinson), anti-
CD1 la (LFA-lx chain) and anti-CD54 (ICAM-1)
(Immunotech, Marseille, France).
Cytokine assay
The generated CD4+ T lymphocytes (1 x 107) were cultured
in AIM-V medium containing 1000 U ml-' of recombinant
IL-2 and 0.05 KE ml-' of OK-432 in a total volume of
10 ml. After 48 h, the supernatants were used for the assay of
cytokines.
In some experiments, CD4+ T cells were stimulated with
immobilised monoclonal antibodies. A 96-well, flat-bottomed
cell culture cluster dish (Costar, Cambridge, MA, USA) was
coated with 10 tgml-' of anti-ICAM-1, anti-LFA-1, or anti-
CD3 monoclonal antibodies. Normal mouse serum contain-
ing 10jg ml' of non-specific IgG was used as the negative
control. After overnight incubation at 4°C, the excess
antibodies were removed and the plates were washed twice
with phosphate-buffered saline (PBS). Then the plates were
used to stimulate CD4+ T lymphocytes by culturing the T
cells (2 x I05 per well) in a total volume of 200 tl for 24 h at
37°C. Cell-free supernatants were harvested and stored at
-20C until quantitation of the IFN-' content.
Cytokines were detected by the two-site sandwich enzyme-
linked immunosorbent assay (ELISA) technique using
monoclonal antibodies to coat the solid phase and as the
secondary antibody. The ELISA kits for IFN-y and IL-4
were obtained from Medgenix (Fleurus, Belgium), while that
for IL-6 was from Toray Industries (Tokyo, Japan), that for
TNF-a came from Otsuka Pharmaceutical (Tokyo, Japan),
and that for TNF-P was from Bender Depl. MedSystems
(Vienna, Austria). Samples were assayed in duplicate and
quantitated by comparison with standard curves obtained
using purified recombinant or natural cytokines.
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Germany) at various effector-target ratios, and were
incubated for 3 h at 37°C.
As a negative control, medium without effector cells was
added, and 0.2% Nonidet P-40 (Sigma) was used as the
positive control. After incubation, 5 ,lI of clarified bovine
haemoglobin (5 mM, Sigma) was added to diminish the back-
ground fluorescence released from lysed target cells. After
measuring the fluorescence intensity of the surviving target
cells with an MPV compact MT (Leitz, Wetzlar, Germany),
the per cent lysis was calculated by the following formula:
Mean experimental reading -
I
mean positive control reading x 100 (%)
Mean negative control reading-
mean positive control reading /
Cell conjugation assay
Conjugation between the CD4+ T cells and target cells was
assessed as described previously with slight modifications
(Martz, 1975; Ozdemirli et al., 1992).
Effector cells (5 x 105) were mixed with target cells
(5 x 104) in total volume of 1001 l in 96-well U-bottomed
micro plates (Costar, Cambridge, MA, USA). After incuba-
tion at 37°C in a humidified carbon dioxide incubator for
3 h, the cells were attached to glass slides using a CF-12D
auto smear (Sakura Seiki, Tokyo, Japan) at 800 r.p.m. for
3 min. The cells were then overlaid with 100 tlI of a mixture
containing 0.05% glutaraldehyde, 2% formaldehyde, 0.025%
calcium chloride and 0.1 M sodium cacodylate in PBS
(pH 7.4), and were fixed by a microwave irradiation at 500 W
for 10 s in a domestic microwave oven (Haruna et al., 1990).
At least 100 target cells were counted under the microscope
and the per cent conjugation was calculated as the number of
conjugated target cells divided by the total number of target
cells. The large target cells were easily distinguished from the
small effector cells and conjugation was arbitrarily defined as
the binding of at least three effector cells to a target cell.
Three different microscopic fields were examined in each
experiment.
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Cytotoxicity assay
The following target cells were used: K562 (a natural killer
(NK)-sensitive myeloid leukemia cell line), Daudi (an NK-
resistant Burkitt's lymphoma cell line), KOA-2 and K-i 19
[anaplastic thyroid carcinoma cell lines established in our
laboratory (Baba et al., 1993; Oka et al., 1993)], and NPA [a
papillary thyroid carcinoma cell line kindly provided by Pro-
fessor S Yamashita; Department of Cell Physiology, Atomic
Disease Institute, Nagasaki University School of Medicine
(Kimura et al., 1992)]. Cytolytic activity was assessed by a
carboxyfluorescein fluorochromasia assay (Bruning et al.,
1980). Briefly, the target cells were labelled with 5-
carboxyfluorescein diacetate (40ljgml-', Sigma) for 1 h at
37°C. Effector T cells were then added to target cells (1 x 104
per well) in a 60-well Terasaki plate (Greiner, Frickenkaiser,
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Figure I Flow cytometric analysis of tumor-infiltrating lym-
phocytes using anti-HLA-DR, anti-CD25, anti-ICAM-1, and
anti-CD3 antibodies (a), and cytotoxicity assay using Daudi and
K562 cells (b). Lymphocytes from patients pretreated with OK-
432/fibrinogen (11) are compared with those from patients
without immunotherapy (E=i). *: p<0.05; **: p<0.01.
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Table I Phenotypic changes and cytotoxic activity of TILs during culture
Weeks of Surface expression (%) Cytotoxicity (%)
culture CD4/T CD8/T HLA-DR/T CD25/T ICAM-JIT K562 Daudi
OK-432/Jbg treated
Case 1 0 74.8 25.2 59.9 15.9 33.0 69.2 55.0
2 96.4 3.6 86.9 79.4 84.6 57.9 56.6
4 95.0 5.0 95.6 53.7 86.9 60.0 54.0
Case 2 0 - - - - - - _
2 83.3 16.7 92.8 77.6 77.9 52.0 89.0
4 98.0 2.0 91.6 76.8 67.1 29.0 65.0
Case 3 0 69.6 30.4 70.8 10.4 39.3 -
2 56.0 44.0 86.5 34.2 76.0 - -
4 99.8 0.2 86.0 67.0 97.0 63.4 72.7
Case 4 0 65.0 35.0 52.2 27.4 72.6 -
2 84.8 15.2 91.4 65.7 97.9 - 21.3
4 96.3 3.7 93.6 54.8 66.7 - 56.1
Case 5 0 67.1 32.9 71.6 28.0 39.2 -
2 88.1 11.9 - - - - -
4 91.8 8.2 99.3 81.9 67.5 63.4 60.7
Case 6 0 84.7 15.3 71.1 13.9 35.1 -
2 72.5 27.5 - - 57.9 - -
4 97.5 2.5 97.3 86.6 95.9 75.8 51.4
Case 7 0 72.8 27.2 53.8 9.8 66.5 23.9 53.0
2 95.9 4.1 84.0 45.0 99.5 47.7 53.6
4 99.1 0.9 99.3 55.7 77.9 35.2 57.8
Control
Case 1 0 55.6 44.4 28.4 13.1 19.9 0.0 0.0
2 16.1 83.9 97.8 11.5 49.5 2.0 0.0
4 1.9 98.1 93.0 18.5 41.2 50.6 53.2
Case 2 0 68.3 31.7 38.9 7.2 4.3 19.8 9.3
2 59.3 40.7 70.7 12.7 33.2 3.6 10.0
4 7.4 92.6 84.8 9.6 51.5 47.6 47.6
Case 3 0 75.1 24.9 37.7 3.4 11.6 12.2 0.0
2 - - _ _ _ _ _
4 - - _ _ _ _ _
Case 4 0 62.4 37.6 51.6 6.9 37.7
2 - - - - _ _ _
4 - - _ _ _ _ _
TILs from patients pretreated with OK-432/fbg (upper panel) and from patients without immunotherapy (lower panel)
were cultured with IL-2 and OK-432, after which phenotypic analysis and the cytotoxicity assay were performed.
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Figure 2 Phenotype of cytotoxic CD4+ T lymphocytes. T cells were stained with phycoerythrin-conjugated and FITC-conjugated
antibodies for analysis by two-color flow cytometry. Data from representative experiments are expressed as contour plots of FITC
and phycoerythrin fluorescence on 4-decade log scales. Quadrant markers were positioned to include >98% of control cells in the
lower left quadrant. The percentage of cells within each quadrant is indicated.
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Cytotoxic T lymphocytes were preincubated with anti-
ICAM-1, anti-LFA-i, anti-CD2 and anti-TCR-i monoclonal
antibodies (2 .tg ml-') for I h at 37C. After washing twice in
AIM-V to remove excess antibodies these effector cells were
used for the cytotoxicity and conjugation assays as described
above.
Results
We analysed TILs from seven thyroid cancer patients who
received intratumoral injection of OK-432/fbg, as well as cells
from four patients without immunotherapy. FACS analysis
of TILs from the former patients showed increased surface
expression of HLA-DR, CD25, and ICAM-1 when compared
with cells from the latter patients (Figure 1).
In the OK-432/fbg group, phenotypic analysis of lym-
phocytes cultured in medium containing recombinant IL-2
revealed that CD4+ T cells gradually increased after repeated
stimulation with OK-432, and accounted for >90%o of all
cells after several weeks. In contrast, CD8+ T lymphocytes
were dominant among cells from the patients without
immunotherapy after the same duration of culture. Following
culture of cells from the OK-432/fbg group with repeated
stimulation for 4 weeks, CD8+ T cells virtually disappeared
and CD4+ T cells reached almost 100% (Table I).
The in v,itro cytotoxicity assay showed that local
immunotherapy considerably enhanced NK and lymphokine
activated killer (LAK) activity of TILs (Figure 1). During
culture, the cytolytic activity of TILs from the OK-432/fbg
group was not reduced despite the expansion of CD4+ T
cells, although TILs from the control group only showed
cytolytic activity when CD8+-LAK cells were generated
(Table I). Figure 2 shows the representative phenotype of
cytotoxic CD4+ T cells from seven patients after culture for
more than 5 weeks. FACS analysis revealed that the pro-
liferating T cells expressed the helper T phenotype (CD4+
Table II Cytokine secretion by cytotoxic CD4+ T cells (pgml-')
IFN-y 46250.0 + 2450.0
TNF-3 5285.0+ 295.0
TNF-a 343.2 ± 64.3
IL-4 <6.0 0.0
IL-6 121.6 14.2
T cells (I x 10') were cultured for 48 h at 37'C in the presence of
IL-2 and OK-432, the supernatants were harvested and were tested
for the indicated cytokines by ELISA. All experiments were
performed in duplicate and the mean + s.d. is presented.
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and Leu8-). The majority of the T cells were positive for T
cell receptor (TCR) 4xB, CD45RO and LFA-1, and the sur-
face expression of HLA-DR, the IL-2 receptor (CD25), and
ICAM-1 gradually increased throughout culture (Table I).
To further characterise these CD4+ T cells, cytokine prod-
uction in culture supernatants was measured by ELISA.
CD4+ T cells stimulated with OK-432 produced high
amounts of IFN- and TNF-Pf but no IL-4 was secreted by
these T cells. Other cytokines, such as TNF-ca and IL-6, were
also detected in the culture supernatants. The results are
summarised in Table II.
The cytotoxicity assay revealed that these T cells exhibited
a high level of killing activity against a broad spectrum of
target cells, including Daudi cells, K562 cells and allogenic
thyroid cancer cell lines (NPA, KOA-2 and K-1 19), but did
not kill autologous or allogenic peripheral blood lymphocytes
(Figure 3). Once activated, the cytotoxic CD4+ T cells did
not require OK-432 to express their cytotoxicity, because
addition of OK-432 to the assay system at various concentra-
tions did not alter the cytolysis of Daudi or K562 cells (data
not shown).
This suggested that the killing activity of these CD4+ T
cells was non-MHC-restricted and that their cytotoxic
activity might be supported by other surface molecules such
as adhesion molecules. To evaluate the role of such molecules
in cytotoxicity we performed an inhibition assay. The
cytotoxicity of CD4+ killer T cells against KOA-2 and K-119
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Figure 3 Cytotoxicity of the generated CD8+ killer ( _ ) and
CD4+ killer ( LII ) T cells for K562 cells, Daudi cells, allogenic
thyroid cancer cell lines, and peripheral blood lymphocytes
(PBL). Cytotoxicity was determined by a 3 h carboxyfluorescein
fluorochromasia assay at an effector target ratio of 10:1. *: Not
tested.
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Figure 4 Inhibition of the cytotoxicity of generated CD8+
( _ ) and CD4+ ( LI ) killer T cells for various tumour cell
lines. Killer T cells were preincubated with the indicated monoc-
lonal antibodies, and the percent inhibition of cytotoxicity for
Daudi cells (a), KOA-2 cells (b), and K 119 cells (c) was cal-
culated. All experiments were performed in triplicate, and data
from one representative experiment is presented.
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Figure 5 Combined inhibition assay of cytotoxicity and conjugation with Daudi cells. CD4+ killer T cells were pretreated with the
indicated antibodies. The right panel shows the percent inhibition of the cytotoxicity of T cells and the left panel shows the percent
inhibition of cell conjugation. Cytotoxic activity and conjugation were examined as described in Materials and methods, and the
percent inhibition was calculated. All experiments were performed in triplicate, and date from one representative experiment is
presented.
Table III Stimulation of IFN-y secretion by cytotoxic CD4+ T cells
incubated with immobilised monoclonal antibodies
Antibody IFN-y
(10 IOgml-,) (pgml')
Control IgG 862.4 ± 50.0
anti-CD3 43765.7 ± 238.7
anti-ICAM-l 4788.7 ± 83.6
anti-LFA-l 883.3 ± 60.5
T cells (2 x 105 per well) were stimulated with the indicated
antibodies immobilized on 96-well culture plates. After 24 h of
incubation at 37'C, supernatants were harvested and IFN-y was
quantitated by ELISA. All experiments were performed in duplicate
and data from one representative experiment is presented.
cells was largely inhibited by anti-LFA-1 and anti-ICAM-1
monoclonal antibodies, while anti-CD2 and anti-TCR-1
antibodies did not have any inhibitory effect. In particular,
only the anti-ICAM-1 antibody inhibited the cytotoxic
activity of these CD4+ killer T cells against Daudi cells
(Figure 4).
To further evaluate the role of the adhesion molecules, we
performed a combined inhibition assay of cell conjugation
and cytotoxicity using CD4+ killer T cells and Daudi cells.
Anti-CD2 and anti-LFA-I monoclonal antibodies reduced
cytotoxic activity by less than 15%, and the per cent inhibi-
tion of cell conjugation was similar. Interestingly, although
anti-ICAM-l pretreatment of the effector CD4+ T cells
inhibited their killing activity, it did not affect cell conjuga-
tion (Figure 5).
As anti-ICAM-l did not inhibit cytolytic activity by block-
ing cell-cell adhesion, it was suggested that ICAM-1 may
have a signal transduction role in lymphocytes that promotes
killing activity. Incubation with immobilised anti-CD3
monoclonal antibody considerably augmented IFN-y secre-
tion by the cytotoxic CD4+ T cells. Interestingly,
immobilised anti-ICAM-1 antibody also enhanced IFN-y
secretion to about five times that seen with control IgG,
although anti-LFA-1 did not (Table III).
Discussion
Both CD4+ and CD8+ T cells can express cytolytic activity
against a variety of antigen-bearing target cells, and cytotoxic
CD4+ T cells can be generated by activation with non-
specific stimulants. OK-432 is a non-specific immunopoten-
tiator of bacterial origin that has been reported to induce
cytotoxic CD4+ T cells in both mice and humans (Ozaki and
Suginoshita, 1989; Ozaki et al., 1990; Nagaoka et al., 1992).
In the present study, we generated cytotoxic CD4+ T lym-
phocytes from the TILs of thyroid cancer patients treated
with our augmented immunisation protocol using OK-432/
fbg (Monden et al., 1992). TILs were used because they are
more effective and have a greater activity against tumour
cells (Rosenberg et al., 1986; Topalian et al., 1987).
Local immunotherapy with OK-432/fbg induces severe
inflammation at the site of injection and in the draining
lymph nodes (Sakita et al., 1993). FACS analysis revealed the
increased expression of HLA-DR, CD25 and ICAM-1 by
TILs about 1 week after the injection of OK-432/fbg. These
TILs also showed high levels of NK and LAK activity. Thus,
our findings suggest that local immunotherapy both activated
T cells that infiltrated the tumour stroma and enhanced the
killing activity of these TILs.
We established cytotoxic CD4+ T cells by culturing TILs
from patients injected with OK-432/fbg in medium contain-
ing recombinant IL-2 and performing repeated stimulation
with OK-432. FACS analysis of the generated killer cells
showed the helper T cell phenotype (negative for CD56, CD8
or Leu8, but positive for CD4). These T cells were also
positive for HLA-DR, CD25, LFA-1 and ICAM-1, which
are markers of activated lymphocytes. Furthermore, the
generated CD4+ killer T cells were memory T cells
(CD45RO+), not naive T cells (CD45RA+) and were positive
for TCRaxp.
To further characterise these CD4+ T cells, cytokine levels
in culture supernatants were measured by ELISA. These cells
produced high amounts of IFN-y and TNF-P, as well as
producing TNFE- and relatively low amounts of IL-6. How-
ever, there was no detectable IL-4 production. Recently, it
has become apparent that in animal models as well as in
humans, CD4+ helper T cells can be categorised into three
main subpopulations based on their functional characteristics
and cytokine production profiles (ThO, TH1, and TH2)
(Wierenga et al., 1991; Romagnani, 1991). Our data suggest
that the generated CD4+ T cells belong to the Thl sub-
population and are so-called 'helper/killer T cells'.
To evaluate the killing activity of these cells, we performed
cytotoxicity assays using several tumour cell lines. The CD4+
T cells exhibited a high level of killing activity against Daudi
cells, K562 cells and allogenic thyroid cancer cell lines,
indicating the ability to lyse a wide variety of tumour cells in
a non-MHC-restricted manner. As the T cells tended to
agglutinate together with the target cells in mixed cultures
and formed clusters within about 30 min, increased
adhesiveness seemed to be important in the killing process.
Inhibition assays involving pretreatment of the T cells with
various antibodies indicated that LFA-1 and ICAM-1, but
not CD2, might play an important role in their cytotoxic
activity. Anti-TCRap antibody did not inhibit their killing
activity, a finding compatible with it being non-MHC
restricted.Generation and analysis of cytotoxic CD4+ T lymphocytes
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Only anti-ICAM-1 antibody inhibited the cytotoxic activity
of the CD4+ killer T cells against Daudi cells, although it did
not affect conjugation between the effector and target cells.
Although ICAM-1 is a potent molecule in cell-cell adhesion,
T cell-Daudi cell binding may have been mediated by other
adhesion molecules after ICAM-1 was blocked by the
antibody. Generally, it has been resolved that the process of
killing by T cells involves three steps: (1) conjugation
formation/activation; (2) lethal hit; and (3)
effector-independent cell lysis (Ozdemirli et al., 1992; Apasov
et al., 1993). Thus, the inhibition of killing for Daudi cell by
anti-ICAM-l was apparently not achieved by blocking
cell-cell attachment, but by blocking some post-binding
event.
It has recently become apparent that several of the
molecules involved in leucocyte adhesion also serve as signal-
ling molecules. LFA-1, ICAM-l, and LFA-3 provide signals
that regulate the lytic ability of LAK and cytotoxic T lym-
phocytes (CTL) effectors, and antibodies to those molecules
enhance the production of IFN-y, TNF-a or TNF-P when
co-immobilised with anti-CD3 Ab (Chong et al., 1992;
Galandrini et al., 1992). The co-stimulatory effects of LFA-1,
LFA-2, and CD45 on T cells are well documented (Denning
et al., 1988; Marvel and Mayer, 1988; Moingeon et al., 1991;
van Seventer et al., 1991), but there have been few investiga-
tions of whether ICAM-1 can also transduce signals in
ICAM-1 expressing killer T cells.
Our experiments show that incubation with an immobilised
anti-CD3 antibody considerably augmented IFN-y secretion
by the cytotoxic CD4+ T cells. An immobilised anti-ICAM-l
antibody also enhanced IFN-y secretion, while immobilised
anti-LFA-1 did not. Cross-linking of surface membrane
receptors with monoclonal antibodies mimics natural
receptor/ligand interactions and thus triggers the same cel-
lular processes (Wachlotz et al., 1989; van Seventer et al.,
1991). Therefore, these data support the concept that ICAM-
1 transmitted signals by interacting with a natural ligand to
enhance cytokine production by the CD4+ T cells. Cross-
linking of ICAM-1 on mononuclear leucocytes induces an
oxidative burst (Rothlein et al., 1994), indicating the
existence of a signalling pathway mediated via this adhesion
molecule.
As IFN-y is a potent regulator of the immune response,
up-regulation of its production by ICAM-1 may contribute
to T cell activation and cytotoxicity. In conclusion, our
findings suggest that the cytolytic activity of CD4+ T cells
generated by OK-432/fbg therapy may be supported by sig-
nal transduction through ICAM-1.
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